{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T12:22:29Z","timestamp":1776601349212,"version":"3.51.2"},"reference-count":58,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["no. 269855"],"award-info":[{"award-number":["no. 269855"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004257","name":"Helse Vest","doi-asserted-by":"publisher","award":["\u00c5pen prosjektst\u00f8tte"],"award-info":[{"award-number":["\u00c5pen prosjektst\u00f8tte"]}],"id":[{"id":"10.13039\/501100004257","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,7,7]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>We aimed to calculate cumulative hepatitis C virus (HCV) treatment coverage among individuals enrolled in opioid agonist therapy (OAT) in Norway between 2013 and 2017 and to document the treatment transition to direct-acting antiviral (DAA) agents. Moreover, we aimed to describe adherence to DAAs in the same cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective cohort, registry data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Specialist healthcare service (secondary)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants and outcomes<\/jats:title>\n                    <jats:p>This observational study was based on data from The Norwegian Prescription Database. We studied dispensed OAT and HCV treatment annually to calculate the cumulative frequency, and employed secondary sources to calculate prevalence, incidence and HCV treatment coverage from 2013 to 2017, among the OAT population. Factors associated with adherence to DAAs were identified a priori and subject to logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>10\u2009371 individuals were identified with dispensed OAT, 1475 individuals of these were identified with dispensed HCV treatment. Annual HCV treatment coverage increased from 3.5% (95% CI: 3.2 to 4.4) in 2013 to 17% (95% CI: 17 to 20) in 2017, giving a cumulative HCV coverage among OAT patients in Norway of 38.5%. A complete shift to interferon-free treatment regimens occurred, where DAAs accounting for 32% of HCV treatments in 2013 and 99% in 2017. About two-thirds of OAT patients were considered adherent to their DAA regimens across all genotypes. High level of OAT continuity was associated with improved adherence to DAAs (adjusted OR 1.4, 95%\u2009CI: 1 to 2, p=0.035).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A large increase in HCV treatment coverage attributed by a complete shift to interferon-free regimens among the Norwegian OAT population has been demonstrated. However, treatment coverage is inadmissibly too low and a further substantial scale-up in HCV treatment is required to reach the universal targets of controlling and eliminating the HCV endemic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-036355","type":"journal-article","created":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T02:15:36Z","timestamp":1598494536000},"page":"e036355","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-9354","authenticated-orcid":false,"given":"Christer Frode","family":"Aas","sequence":"first","affiliation":[{"name":"Department of Addiction Medicine, Helse Bergen HF, Bergen, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn Henrik","family":"Vold","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Helse Bergen HF, Bergen, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Skurtveit","sequence":"additional","affiliation":[{"name":"Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway"},{"name":"Norwegian Centre for Addiction Research, University of Oslo, Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingvild","family":"Odsbu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Chalabianloo","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Helse Bergen HF, Bergen, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Magnus","family":"\u00d8kland","sequence":"additional","affiliation":[{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael Alexander Modahl","family":"Leiva","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Helse Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[{"name":"London School of Hygiene and Tropical Medicine, London, UK"},{"name":"School of Social and Community Medicine, University of Bristol, Bristol, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Helse Bergen HF, Bergen, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8757-2092","authenticated-orcid":false,"given":"Lars T","family":"Fadnes","sequence":"additional","affiliation":[{"name":"Department of Addiction Medicine, Helse Bergen HF, Bergen, Norway"},{"name":"Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,8,26]]},"reference":[{"key":"2025121508174220000_10.8.e036355.1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26141"},{"key":"2025121508174220000_10.8.e036355.2","unstructured":"World Health Organization . Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection, 2018."},{"key":"2025121508174220000_10.8.e036355.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61097-0"},{"key":"2025121508174220000_10.8.e036355.4","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2025121508174220000_10.8.e036355.5","unstructured":"Waal HBK , Clausen T , Lillevold PH , et al . Seraf report 2017: status MAR 20 years. status, evaluations and perspectives: the Norwegian centre for addiction research (Seraf, 2018."},{"key":"2025121508174220000_10.8.e036355.6","unstructured":"Ministry of Health and Care Services . National strategy against hepatitis 2018 - 2023: Ministry of Health and Care Services, 2018."},{"key":"2025121508174220000_10.8.e036355.7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jhep.2017.10.010","article-title":"Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe","volume":"68","author":"Fraser","year":"2018","journal-title":"J Hepatol"},{"key":"2025121508174220000_10.8.e036355.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2015.07.005"},{"key":"2025121508174220000_10.8.e036355.9","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(17)30373-X"},{"key":"2025121508174220000_10.8.e036355.10","first-page":"129","volume-title":"A method to estimate total entry to hard drug use: the case of intravenous drug use in Norway, European addiction research","volume":"17","author":"Amundsen","year":"2011"},{"key":"2025121508174220000_10.8.e036355.11","unstructured":"European Monitoring Centre for Drugs and Drug Addiction . Country drug report 2018. Norway, 2018."},{"key":"2025121508174220000_10.8.e036355.12","unstructured":"The Norwegian Institute of Public Health . Drugs in Norway: problematic use of drugs. The Norwegian Institute of Public Health, 2018."},{"key":"2025121508174220000_10.8.e036355.13","unstructured":"The Norwegian Institute of Public Health . Hepatitis C - guidelines for health professionals. The Norwegian Institue of Public Health, 2019."},{"key":"2025121508174220000_10.8.e036355.14","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2631-2","article-title":"Modelling the burden of hepatitis C infection among people who inject drugs in Norway, 1973-2030","volume":"17","author":"Meijerink","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2025121508174220000_10.8.e036355.15","article-title":"Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs","volume":"9","author":"Platt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121508174220000_10.8.e036355.16","article-title":"Oral substitution treatment of injecting opioid users for prevention of HIV infection","author":"Gowing","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121508174220000_10.8.e036355.17","unstructured":"Waal HBK , Clausen T , H\u00e5seth A , et al . Seraf report: status report 2013. The Norwegian Centre of Addiction Reserach (SERAF), 2014."},{"key":"2025121508174220000_10.8.e036355.18","unstructured":"Waal HBK , Clausen T , H\u00e5seth A , et al . Seraf report: status 2014, an aging MAR-population? The Norwegian Centre for Addiction Research (SERAF), 2015."},{"key":"2025121508174220000_10.8.e036355.19","unstructured":"Waal HBK , Clausen T , H\u00e5seth A , et al . Seraf report: status report 2015. The Norwegian Centre for Addiction Research, 2016."},{"key":"2025121508174220000_10.8.e036355.20","unstructured":"Waal HBK , Clausen T , H\u00e5seth A , et al . Seraf report: status 2016. The Norwegian Centre for Addiction Reserach (SERAF), 2017."},{"key":"2025121508174220000_10.8.e036355.21","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4598-7","article-title":"Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV)","volume":"19","author":"Fadnes","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025121508174220000_10.8.e036355.22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26431"},{"key":"2025121508174220000_10.8.e036355.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01080.x"},{"key":"2025121508174220000_10.8.e036355.24","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1093\/cid\/cit306","article-title":"Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis","volume":"57 Suppl 2","author":"Aspinall","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025121508174220000_10.8.e036355.25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1007"},{"key":"2025121508174220000_10.8.e036355.26","unstructured":"World Health Organization . Newsroom: hepatitis C. World Health Organization (WHO), 2018."},{"key":"2025121508174220000_10.8.e036355.27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166451","article-title":"Hepatitis C treatment uptake among patients who have received opioid substitution treatment: a population-based study","volume":"11","author":"Midgard","year":"2016","journal-title":"PLoS One"},{"key":"2025121508174220000_10.8.e036355.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179764","article-title":"Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study","volume":"12","author":"Dalgard","year":"2017","journal-title":"PLoS One"},{"key":"2025121508174220000_10.8.e036355.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"2025121508174220000_10.8.e036355.30","doi-asserted-by":"crossref","first-page":"345-353","DOI":"10.1111\/liv.13240","article-title":"The cost impact of outreach testing and treatment for hepatitis C in an urban drug treatment unit","volume":"37","author":"Selvapatt","year":"2017","journal-title":"Liver Int"},{"key":"2025121508174220000_10.8.e036355.31","article-title":"The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C","author":"Younossi","journal-title":"Dig Liver Dis"},{"key":"2025121508174220000_10.8.e036355.32","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1152"},{"key":"2025121508174220000_10.8.e036355.33","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1336"},{"key":"2025121508174220000_10.8.e036355.34","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13081"},{"key":"2025121508174220000_10.8.e036355.35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/liv.13240","article-title":"The cost impact of outreach testing and treatment for hepatitis C in an urban drug treatment unit","volume":"37","author":"Selvapatt","year":"2017","journal-title":"Liver Int"},{"key":"2025121508174220000_10.8.e036355.36","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1007\/s10620-019-05590-x","article-title":"Determinants of hepatitis C treatment adherence and treatment completion among veterans in the direct acting antiviral era","volume":"64","author":"Patel","year":"2019","journal-title":"Dig Dis Sci"},{"key":"2025121508174220000_10.8.e036355.37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.aohep.2018.06.001","article-title":"Barriers to treatment of chronic hepatitis C with direct acting antivirals in an urban clinic","volume":"18","author":"Malespin","year":"2019","journal-title":"Ann Hepatol"},{"key":"2025121508174220000_10.8.e036355.38","unstructured":"World Health Organization . WHO Guidlines for the screening, care and treatment for persons with chronic hepatitis C infection. WHO, 2016."},{"key":"2025121508174220000_10.8.e036355.39","unstructured":"The Norwegian Prescription Database (NorPD). . About the Norwegian prescription database. The Norwegian Institute of Public Health, 2019."},{"key":"2025121508174220000_10.8.e036355.40","unstructured":"WHO . Who collaborating centre for drug statistics methodology. ATC classification index with DDDs 2018, 2018."},{"key":"2025121508174220000_10.8.e036355.41","unstructured":"The World Health Organization Collaborating Centre for Drug Statistics Methodology . Definition and general considerations. World Health Organization, 2019."},{"key":"2025121508174220000_10.8.e036355.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2014.07.014"},{"key":"2025121508174220000_10.8.e036355.43","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.12370","article-title":"Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner City residents","volume":"34","author":"Alavi","year":"2014","journal-title":"Liver Int"},{"key":"2025121508174220000_10.8.e036355.44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.drugpo.2017.05.054","article-title":"Restrictions on access to direct-acting antivirals for people who inject drugs: the European Hep-CORE study and the role of patient groups in monitoring national HCV responses","volume":"47","author":"Lazarus","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2025121508174220000_10.8.e036355.45","unstructured":"Alcorn K . European HCV treatment access survey shows big variations in eligibility. AIDSmap 2017."},{"key":"2025121508174220000_10.8.e036355.46","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jvh.12875","article-title":"Hepatitis C: the beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe","volume":"25 Suppl 1","author":"Papatheodoridis","year":"2018","journal-title":"J Viral Hepat"},{"key":"2025121508174220000_10.8.e036355.47","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-3918-2","article-title":"Integrated care of severe infectious diseases to people with substance use disorders; a systematic review","volume":"19","author":"Vold","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025121508174220000_10.8.e036355.48","unstructured":"Ministry of Health and Care Services . National guidline for medicaly assisted rehabilitation (MAR) for opioid dependence. The Norwegian Ministry of health and care services, 2010."},{"key":"2025121508174220000_10.8.e036355.49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.drugpo.2018.08.013","article-title":"Adherence to sofosbuvir and Velpatasvir among people with chronic HCV infection and recent injection drug use: the simplify study","volume":"62","author":"Cunningham","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2025121508174220000_10.8.e036355.50","doi-asserted-by":"crossref","unstructured":"Cunningham EB , Hajarizadeh B , Amin J , et al . Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy. Clinical Infectious Diseases 2019.doi:10.1093\/cid\/ciz1089","DOI":"10.1093\/cid\/ciz1089"},{"key":"2025121508174220000_10.8.e036355.51","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.drugpo.2017.05.025","article-title":"Understanding real-world adherence in the directly acting antiviral era: a prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada","volume":"47","author":"Mason","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2025121508174220000_10.8.e036355.52","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/jvh.13175","article-title":"Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection","volume":"26","author":"Read","year":"2019","journal-title":"J Viral Hepat"},{"key":"2025121508174220000_10.8.e036355.53","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S2468-1253(18)30304-2","article-title":"Direct-Acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis","volume":"3","author":"Hajarizadeh","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121508174220000_10.8.e036355.54","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s00228-018-2456-y","article-title":"Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden","volume":"74","author":"Frisk","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"2025121508174220000_10.8.e036355.55","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/cid\/cit301","article-title":"Hepatitis C virus reinfection following treatment among people who use drugs","volume":"57 Suppl 2","author":"Grady","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2025121508174220000_10.8.e036355.56","first-page":"347","volume-title":"Treatment of chronic hepatitis C in patients receiving opioid agonist therapy: a review of best practice, infectious disease clinics of North America","volume":"32","author":"Norton","year":"2018"},{"key":"2025121508174220000_10.8.e036355.57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5694\/j.1326-5377.1991.tb121030.x","article-title":"Methadone dosage and retention of patients in maintenance treatment","volume":"154","author":"Caplehorn","year":"1991","journal-title":"Med J Aust"},{"key":"2025121508174220000_10.8.e036355.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.012"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-036355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:17:53Z","timestamp":1765815473000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-036355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,8,26]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/bmjopen-2019-036355"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-036355","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13529\/v1","asserted-by":"object"}]},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}